Dermatology – Medxy AI

Routine Whole‑Body Imaging Did Not Improve Early Survival in High‑Risk Melanoma: Interim TRIM Trial Analysis

By MedXY 11/05/2025

Interim results from the multicentre phase 3 TRIM trial show no survival benefit from adding scheduled whole‑body CT or FDG‑PET‑CT to physical‑examination follow‑up after radical surgery for stage IIB–C and III cutaneous melanoma at median 33.6 months.

Dermatology Diabetes & Endocrinology news

SGLT2 Inhibitors Linked to Lower Risk of New-Onset Atopic Dermatitis in People with Type 2 Diabetes

By MedXY 11/01/2025

A nationwide Taiwanese active-comparator cohort found SGLT2 inhibitor use was associated with a lower incidence of new-onset atopic dermatitis compared with DPP‑4 inhibitors; the effect persisted across sensitivity analyses, showed a dose-response relation and was stronger in men.

Dermatology Diabetes & Endocrinology news

SGLT2 Inhibitors Associated with Lower Risk of New-Onset Atopic Dermatitis in People with Type 2 Diabetes: Nationwide Active-Comparator Cohort Study

By MedXY 11/01/2025

A Taiwanese nationwide cohort study found SGLT2 inhibitor use linked to a lower incidence of new-onset atopic dermatitis versus DPP4 inhibitors (IPTW-adjusted HR 0.847), with a dose-response effect and stronger protection in men.

Allergy & Immunology Dermatology news

Rilzabrutinib in Moderate-to-Severe Atopic Dermatitis: Assessing Efficacy and Safety in a Phase II Trial

By MedXY 10/28/2025

A phase II trial evaluating rilzabrutinib, a BTK inhibitor, in moderate-to-severe atopic dermatitis showed no significant improvement in primary endpoints but demonstrated rapid itch relief and a favorable safety profile.

Dermatology news

Comparative Efficacy and Safety of Treatments for Moderate to Severe Hidradenitis Suppurativa: Insights from a Living Network Meta-Analysis

By MedXY 10/27/2025

This living systematic review and network meta-analysis evaluates efficacy, safety, and tolerability of medical treatments for moderate to severe hidradenitis suppurativa, highlighting top-performing agents and informing clinical decision-making.

Dermatology news Pediatrics

Oral Manifestations of Lamellar Ichthyosis: A Case Report of Two Siblings

By MedXY 10/25/2025

Two brothers with lamellar ichthyosis presented with enamel defects and dental caries; dental rehabilitation with preventive measures was completed alongside dermatologic care.

Dermatology news Plastic Surgery

Optimizing Scar Healing Post-Dermatologic Surgery: A Comparative Look at Hydrocolloid Dressings and Petroleum Ointments

By MedXY 10/25/2025

This study evaluates whether a single application of hydrocolloid dressing improves scar appearance and reduces complications compared to daily petroleum ointment after dermatologic excisions.

Dermatology Oncology

Nine-Year Outcomes of Nivolumab vs Ipilimumab in Resected Stage III/IV Melanoma: Sustained Survival Benefit and Safety

By MedXY 10/25/2025

The 9-year follow-up of the CheckMate 238 trial confirms that nivolumab offers longer recurrence-free survival than ipilimumab in resected stage III/IV melanoma, with durable safety and favorable distant metastasis-free survival.

Dermatology news Plastic Surgery

Enhancing Surgical Outcomes: Hydrocolloid Dressings vs Petroleum Ointment for Scar Management

By MedXY 10/24/2025

This clinical trial compares the effectiveness and safety of hydrocolloid dressings versus petroleum ointment in post-surgical scar healing, emphasizing patient comfort and cosmetic outcomes.

Dermatology Hematology-Oncology news

T-Cell Receptor Clonotypes as Prognostic Markers in Cutaneous T-Cell Lymphoma: Insights from Next-Generation Sequencing

By MedXY 10/24/2025

This study identifies specific T-cell receptor clonotypes associated with aggressive subtypes and poorer survival in mycosis fungoides and Sézary syndrome, supporting TCR sequencing as a tool for refined risk stratification in cutaneous T-cell lymphoma.

Dermatology Pediatrics

Baricitinib Shows Promising Results in Restoring Hair Growth in Adolescents with Severe Alopecia Areata: Phase 3 BRAVE-AA-PEDS Trial

By MedXY 10/24/2025

The phase 3 BRAVE-AA-PEDS trial demonstrates that baricitinib, a JAK inhibitor, significantly restores scalp, eyebrow, and eyelash hair in adolescents with severe alopecia areata, achieving up to 80% hair regrowth in recent-onset cases after one year of treatment.

Dermatology General Surgery Oncology

Refining Sentinel Lymph Node Biopsy Decisions in Melanoma: Insights from the MERLIN_001 Gene Expression Profiling Study

By MedXY 10/24/2025

The MERLIN_001 study validates a combined clinicopathological and gene expression profile test that accurately predicts sentinel lymph node metastasis risk in patients with cutaneous melanoma, potentially guiding safer, more personalized surgical decisions.

Dermatology HIV/AIDS Specialties

Evolving Dermatologic Landscape in HIV: Prevalence, Incidence, and Risk Factors in the Modern ART Era from the DC Cohort

By MedXY 10/22/2025

Despite advances in antiretroviral therapy, dermatologic diseases remain prevalent in people with HIV, with incidence declining yet significant disparities persisting related to immune status, demographics, and structural factors.

Dermatology Nephrology news

Enhancing Skin Cancer Surveillance in Solid Organ Transplant Recipients: Impact of the KP-SUNTRAC Risk-Based Program

By MedXY 10/15/2025

A retrospective cohort study demonstrates that implementation of KP-SUNTRAC increases targeted skin cancer screening and detection among high-risk solid organ transplant recipients without increasing health care utilization.

Dermatology Hematology-Oncology news

Prognostic Markers and Survival Outcomes in Advanced Mycosis Fungoides and Sézary Syndrome: Insights from the Cutaneous Lymphoma International Consortium

By MedXY 10/14/2025

A large international study identified key prognostic markers affecting survival in advanced-stage mycosis fungoides and Sézary syndrome, enabling risk stratification and guiding clinical management.

Dermatology Hematology-Oncology news

Large-Cell Transformation of Mycosis Fungoides: Clinical Patterns, Prognostic Insights, and Implications for Staging

By MedXY 10/14/2025

Large-cell transformation in mycosis fungoides marks an aggressive disease subset with distinct prognostic groups and poor survival, highlighting the need for tailored treatment and integration into staging systems.

Dermatology Hematology-Oncology news

CLIPI: A New Prognostic Index Transforming Risk Stratification in Advanced Cutaneous Lymphomas

By MedXY 10/14/2025

The CLIPI prognostic index refines risk stratification in advanced mycosis fungoides and Sézary syndrome, identifying distinct survival groups to guide personalized treatment decisions and improve outcomes.

Clinical Updates Dermatology news Specialties

Once-Daily Oral Icotrokinra vs Placebo and Deucravacitinib in Moderate-to-Severe Plaque Psoriasis: Insights from ICONIC-ADVANCE 1 & 2 Phase 3 Trials

By MedXY 10/10/2025

ICONIC-ADVANCE 1 & 2 phase 3 trials demonstrate that once-daily oral icotrokinra significantly improves skin clearance with superior efficacy and favorable safety compared to placebo and deucravacitinib in moderate-to-severe plaque psoriasis.

Dermatology Gastroenterology

IL23R Polymorphism as a Genetic Predictor of Paradoxical Psoriasis in Anti-TNFα-Treated IBD Patients

By MedXY 10/09/2025

The IL23R1142G>A genetic variant strongly predicts paradoxical psoriasis in inflammatory bowel disease patients undergoing anti-TNFα therapy, guiding personalized treatment decisions.

Allergy & Immunology Dermatology news

Patient-Centered Insights: Understanding Treatment Preferences in Chronic Urticaria Management

By MedXY 10/08/2025

This systematic review highlights patient and caregiver priorities in chronic urticaria treatment, emphasizing rapid symptom relief, long-term effectiveness, and safety.